A Review of the Evidence for Use of Thymoglobulin Induction in Renal Transplantation

Transplantation Proceedings

Volumn 42, Issue 5, 2010, Pages 1395-1400

  Gaber, A Osama ^a,b   Knight, R J ^a   Patel, S ^a   Gaber, L W ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; EQUINE ANTITHYMOCYTE GLOBULIN; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEVER; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; GRAFT REJECTION; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY TRANSPLANTATION; RABBITS; REGISTRIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77953678252     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.04.019     Document Type: Article

References (19)

1. Issa N.C., and Fishman J.A. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 48 (2009) 772
2. Patlolla V., Zhong X., Reed G.W., et al. Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant 7 (2007) 1832
3. Jindal R.M., Das N.P., Neff R.T., et al. Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database. Am J Nephrol 29 (2009) 501
4. Willoughby L.M., Schnitzler M.A., Brennan D.C., et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons. Transplantation 87 (2009) 1520
5. Brennan D., Flavin K., Lowell J., et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 67 (1999) 1011
6. Hardinger K.L., Schnitzler M.A., Miller B., et al. Five-year follow up of Thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 78 (2004) 136
7. Hardinger K.L., Rhee S., Buchanan P., et al. A prospective, randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 86 (2008) 947
8. Hardinger K., Schnitzler M., Miller B., et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 78 (2004) 136
9. Brennan D., Daller J., and Lake K. Rabbit antithymocyte globulin versus basiliximab for induction in renal transplantation. N Engl J Med 355 (2006) 9
10. Brennan D.C., and Schnitzler M.A. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 359 (2008) 1736
11. Noel C., Abramowicz D., Durand D., et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 20 (2009) 1385
12. Mandelbrot D. Anti-IL-2 receptor antibodies versus anti-thymocyte globulin for induction therapy in kidney transplantation. J Am Soc Nephrol 20 (2009) 1170
13. Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant 9 suppl 3 (2009) S1
14. Lebranchu Y., Bridoux F., Buchler M., et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2 (2002) 48
15. Mourad G., Rostaing L., Legendre C., et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78 (2004) 584
16. Ciancio G., Burke G., Gaynor J., et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 22 (2008) 200
17. Abou-Ayache R., Buchler M., Lepogamp P., et al. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. Nephrol Dial Transplant 23 (2008) 2024
18. Mourad G., Garrigue V., Squifflet J., et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 72 (2001) 1050
19. Charpentier B., Rostaing L., Berthoux F., et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 75 (2003) 844